{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T02:00:12Z","timestamp":1773280812440,"version":"3.50.1"},"reference-count":33,"publisher":"American Veterinary Medical Association (AVMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ajvr"],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:sec id=\"s001\">\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To determine the effects of orally administered raltegravir in cats with experimentally induced ocular and respiratory feline herpesvirus-1 (FHV-1) infection.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s002\">\n<jats:title>ANIMALS<\/jats:title>\n<jats:p>14 healthy 6-month-old unvaccinated specific pathogen\u2013free cats.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s003\">\n<jats:title>PROCEDURES<\/jats:title>\n<jats:p>On day 0, all cats were experimentally inoculated by topical application of 0.1 mL of a solution containing 10<jats:sup>6<\/jats:sup> plaque-forming units of FHV-1 strain FH2CS to the inferior conjunctival fornix of each eye. Cats were randomly assigned to receive either raltegravir (80 mg; n = 7) or lactose (250 mg; vehicle; 7), PO, every 12 hours for 14 days beginning on day 1. Cats were assigned clinical ocular and respiratory disease scores every other day from days 0 to 30. Conjunctival swab specimens were collected for detection of FHV-1 by virus isolation and real-time PCR assay at 3-day intervals from days 0 to 30. Confocal microscopy was performed on days 0 and 10 to assess corneal epithelial leukocyte infiltration. The assessed variables and duration of FHV-1 shedding were compared between the 2 treatment groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s004\">\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Cats in both groups developed moderate to severe conjunctivitis and ulcerative keratitis characteristic of FHV-1 infection. Median duration of FHV-1 shedding was shorter and signs of ocular and respiratory disease were less severe for raltegravir-treated cats than for vehicle-treated cats. However, the mean conjunctival FHV-1 titer and corneal epithelial leukocyte count did not differ between the 2 groups.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"s005\">\n<jats:title>CONCLUSIONS AND CLINICAL RELEVANCE<\/jats:title>\n<jats:p>Results suggested orally administered raltegravir might be effective for alleviation of ocular and respiratory signs of FHV-1 infection in cats. (<jats:italic>Am J Vet Res<\/jats:italic> 2019;80:490\u2013497)<\/jats:p>\n<\/jats:sec>","DOI":"10.2460\/ajvr.80.5.490","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T16:11:43Z","timestamp":1556554303000},"page":"490-497","source":"Crossref","is-referenced-by-count":8,"title":["Effects of orally administered raltegravir in cats with experimentally induced ocular and respiratory feline herpesvirus-1 infection"],"prefix":"10.2460","volume":"80","author":[{"given":"Chloe B.","family":"Spertus","sequence":"first","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew R.","family":"Pennington","sequence":"additional","affiliation":[{"name":"2Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerlinde R.","family":"Van de Walle","sequence":"additional","affiliation":[{"name":"2Baker Institute for Animal Health, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary I.","family":"Badanes","sequence":"additional","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie E.","family":"Judd","sequence":"additional","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussni O.","family":"Mohammed","sequence":"additional","affiliation":[{"name":"3Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C.","family":"Ledbetter","sequence":"additional","affiliation":[{"name":"1Department of Clinical Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1272","reference":[{"key":"ref1","series-title":"J Feline Med Surg","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.jfms.2011.03.010","article-title":"Feline herpesvirus-1: ocular manifestations, diagnosis and treatment options","volume":"13","author":"Gould","year":"2011"},{"key":"ref2","series-title":"J Am Vet Med Assoc","first-page":"502","article-title":"Evaluation of serologic and viral detection methods for diagnosing feline herpesvirus-1 infection in cats with acute respiratory tract or chronic ocular disease","volume":"214","author":"Maggs","year":"1999"},{"key":"ref3","series-title":"J Feline Med Surg","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1053\/jfms.2001.0110","article-title":"Ocular manifestations of feline herpesvirus","volume":"3","author":"Andrew","year":"2001"},{"key":"ref4","series-title":"Vet Res","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1051\/vetres:2006063","article-title":"Feline herpesvirus","volume":"38","author":"Gaskell","year":"2007"},{"key":"ref5","series-title":"Vet Rec","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1136\/vr.100.7.128","article-title":"Experimental induction of feline viral rhinotracheitis virus re-excretion in FVR-recovered cats","volume":"100","author":"Gaskell","year":"1977"},{"key":"ref6","series-title":"Vet J","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.tvjl.2013.11.018","article-title":"Ocular manifestations of feline viral diseases","volume":"201","author":"Stiles","year":"2014"},{"key":"ref7","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2460\/ajvr.72.1.85","article-title":"Evaluation of orally administered famciclovir in cats experimentally infected with feline herpesvirus type-1","volume":"72","author":"Thomasy","year":"2011"},{"issue":"suppl 1","key":"ref8","series-title":"Vet Ophthalmol","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/vop.12375","article-title":"A review of antiviral drugs and other compounds with activity against feline herpesvirus type 1","volume":"19","author":"Thomasy","year":"2016"},{"key":"ref9","series-title":"J Am Vet Med Assoc","doi-asserted-by":"publisher","first-page":"526","DOI":"10.2460\/javma.249.5.526","article-title":"Oral administration of famciclovir for treatment of spontaneous ocular, respiratory, or dermatologic disease attributed to feline herpesvirus type 1: 59 cases (2006\u20132013)","volume":"249","author":"Thomasy","year":"2016"},{"key":"ref10","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2460\/ajvr.69.2.289","article-title":"Effect of topical ophthalmic application of cidofovir on experimentally induced primary ocular feline herpesvirus-1 infection in cats","volume":"69","author":"Fontenelle","year":"2008"},{"key":"ref11","series-title":"MBio","first-page":"e01318","article-title":"HIV integrase inhibitors block replication of alpha-, beta-, and gammaherpesviruses","volume":"5","author":"Yan","year":"2014"},{"key":"ref12","series-title":"Medicine (Baltimore)","doi-asserted-by":"publisher","first-page":"e4886","DOI":"10.1097\/MD.0000000000004886","article-title":"Cross-sectional study of virological failure and multinucleoside reverse transcriptase inhibitor resistance at 12 months of antiretroviral therapy in Western India","volume":"95","author":"Karade","year":"2016"},{"key":"ref13","series-title":"Proc Natl Acad Sci U S A","doi-asserted-by":"publisher","first-page":"16078","DOI":"10.1073\/pnas.1007144107","article-title":"Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain","volume":"107","author":"Nadal","year":"2010"},{"key":"ref14","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"11121","DOI":"10.1128\/JVI.01540-14","article-title":"A mutation in the DNA polymerase accessory factor of herpes simplex virus 1 restores viral DNA replication in the presence of raltegravir","volume":"88","author":"Zhou","year":"2014"},{"key":"ref15","series-title":"Antiviral Res","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.antiviral.2014.12.013","article-title":"The processivity factor complex of feline herpes virus-1 is a new drug target","volume":"115","author":"Zhukovskaya","year":"2015"},{"key":"ref16","series-title":"Clin Infect Dis","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1086\/597290","article-title":"Raltegravir: the first HIV type 1 integrase inhibitor","volume":"48","author":"Hicks","year":"2009"},{"key":"ref17","series-title":"Vet Microbiol","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.vetmic.2011.03.039","article-title":"Inhibition of feline leukemia virus replication by the integrase inhibitor raltegravir","volume":"152","author":"Cattori","year":"2011"},{"key":"ref18","series-title":"J Gen Virol","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1099\/vir.0.039909-0","article-title":"Discovery of drugs that possess activity against feline leukemia virus","volume":"93","author":"Greggs WM","year":"2012"},{"key":"ref19","series-title":"Vet Microbiol","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.vetmic.2014.10.031","article-title":"Evaluation of the effect of short-term treatment with the integrase inhibitor raltegravir (Isentress) on the course of progressive feline leukemia virus infection","volume":"175","author":"Boesch","year":"2015"},{"key":"ref20","series-title":"J Gen Virol","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1099\/jgv.0.000451","article-title":"A novel corneal explant model system to evaluate antiviral drugs against feline herpesvirus type 1 (FHV-1)","volume":"97","author":"Pennington","year":"2016"},{"key":"ref21","series-title":"Statement for the use of animals in ophthalmic and vision research","year":"2018"},{"key":"ref22","series-title":"Am J Vet Res","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2460\/ajvr.70.4.513","article-title":"Experimental primary ocular canine herpesvirus-1 infection in adult dogs","volume":"70","author":"Ledbetter","year":"2009"},{"key":"ref23","series-title":"J Ocul Pharmacol Ther","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1089\/jop.2015.0024","article-title":"In vitro and in vivo evaluation of cidofovir as a topical ophthalmic antiviral for ocular canine herpesvirus-1 infections in dogs","volume":"31","author":"Ledbetter","year":"2015"},{"key":"ref24","series-title":"Cornell Vet","first-page":"232","article-title":"Feline viruses. VII. Immunity to the feline herpesvirus in kittens inoculated experimentally by the aerosol method","volume":"60","author":"Walton","year":"1970"},{"key":"ref25","series-title":"mSphere","first-page":"e00039","article-title":"Electric cell-substrate impedance sensing to monitor viral growth and study cellular responses to infection with alphaherpesviruses in real time","volume":"2","author":"Pennington","year":"2017"},{"key":"ref26","series-title":"Mol Biol Int","first-page":"587680","article-title":"GAPDH pseudogenes and the quantification of feline genomic DNA equivalents","volume":"2013","author":"Helfer-Hungerbuehler","year":"2013"},{"key":"ref27","series-title":"Drug Metab Dispos","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1124\/dmd.107.016196","article-title":"Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme","volume":"35","author":"Kassahun","year":"2007"},{"key":"ref28","series-title":"BMC Genomics","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1186\/s12864-017-4283-4","article-title":"Phylogenetic and recombination analysis of the herpesvirus genus varicellovirus","volume":"18","author":"Kolb","year":"2017"},{"key":"ref29","series-title":"BMC Genomics","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12864-016-3050-2","article-title":"Low genetic diversity among historical and contemporary clinical isolates of felid herpesvirus 1","volume":"17","author":"Vaz","year":"2016"},{"key":"ref30","series-title":"Virology","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.virol.2018.03.018","article-title":"Genomic, recombinational and phylogenetic characterization of global feline herpesvirus 1 isolates","volume":"518","author":"Lewin","year":"2018"},{"key":"ref31","series-title":"J Virol","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1128\/JVI.75.4.1761-1769.2001","article-title":"Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir","volume":"75","author":"Sarisky","year":"2001"},{"key":"ref32","series-title":"Antiviral Res","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/0166-3542(91)90010-O","article-title":"The implications of resistance to antiviral agents for herpesvirus drug targets and drug therapy","volume":"15","author":"Coen","year":"1991"},{"key":"ref33","series-title":"J Infect Dis","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1086\/591913","article-title":"Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults","volume":"198","author":"Mark","year":"2008"}],"container-title":["American Journal of Veterinary Research"],"original-title":[],"link":[{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/80\/5\/ajvr.80.5.490.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/80\/5\/ajvr.80.5.490.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/avmajournals.avma.org\/downloadpdf\/journals\/ajvr\/80\/5\/ajvr.80.5.490.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T20:41:53Z","timestamp":1696538513000},"score":1,"resource":{"primary":{"URL":"https:\/\/avmajournals.avma.org\/view\/journals\/ajvr\/80\/5\/ajvr.80.5.490.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":33,"journal-issue":{"issue":"5"},"URL":"https:\/\/doi.org\/10.2460\/ajvr.80.5.490","relation":{},"ISSN":["0002-9645"],"issn-type":[{"value":"0002-9645","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}